AIMS: The objective of this study was to evaluate the accuracy, ease of use and reproducibility of chromogenic in situ hybridisation (CISH) for HER2 testing by studying its inter-laboratory concordance in five Australian pathology laboratories. METHODS: The HER2 status of 49 breast cancers was determined by CISH twice in two different laboratories. Each sample had previously been tested by immunohistochemistry (IHC; 2+ and 3+ cases selected) and fluorescence in situ hybridisation (FISH). Participating laboratories were blinded to these test results. Oestrogen receptor (ER) status was also evaluated for each cancer. RESULTS: High correlation was observed between FISH and CISH results. No cases showing high gene amplification by FISH were scored as non-amplified by CISH (kappa coefficient = 1). High correlation was observed between IHC and CISH, all IHC 3+ samples showing amplification by CISH. Inter-laboratory CISH concordance was also good (kappa coefficient = 0.67). Fifty-six per cent of HER2-amplified samples tested ER positive, while 42% of ER-positive cases showed HER2 gene amplification, confirming that HER2 testing should not be confined to ER-negative breast cancers. CONCLUSIONS: These findings demonstrate that CISH is a robust test to assess HER2 status in breast cancer and therefore is an important addition to the HER2 testing algorithm.
AIMS: The objective of this study was to evaluate the accuracy, ease of use and reproducibility of chromogenic in situ hybridisation (CISH) for HER2 testing by studying its inter-laboratory concordance in five Australian pathology laboratories. METHODS: The HER2 status of 49 breast cancers was determined by CISH twice in two different laboratories. Each sample had previously been tested by immunohistochemistry (IHC; 2+ and 3+ cases selected) and fluorescence in situ hybridisation (FISH). Participating laboratories were blinded to these test results. Oestrogen receptor (ER) status was also evaluated for each cancer. RESULTS: High correlation was observed between FISH and CISH results. No cases showing high gene amplification by FISH were scored as non-amplified by CISH (kappa coefficient = 1). High correlation was observed between IHC and CISH, all IHC 3+ samples showing amplification by CISH. Inter-laboratory CISH concordance was also good (kappa coefficient = 0.67). Fifty-six per cent of HER2-amplified samples tested ER positive, while 42% of ER-positive cases showed HER2 gene amplification, confirming that HER2 testing should not be confined to ER-negative breast cancers. CONCLUSIONS: These findings demonstrate that CISH is a robust test to assess HER2 status in breast cancer and therefore is an important addition to the HER2 testing algorithm.
Authors: Sabine Riethdorf; Bernhard Hoegel; Birgit John; German Ott; Peter Fritz; Susanne Thon; Thomas Loening; Klaus Pantel Journal: J Cancer Res Clin Oncol Date: 2010-04-16 Impact factor: 4.553
Authors: Evangelos Tsiambas; Nicholas S Mastronikolis; Alicia Y Lefas; Stavros N Georgiannos; Vasileios Ragos; Panagiotis P Fotiades; Nikolaos Tsoukalas; Nikolaos Kavantzas; Andreas Karameris; Dimitrios Peschos; Efstratios Patsouris; Konstantinos Syrigos Journal: In Vivo Date: 2017 Jul-Aug Impact factor: 2.155
Authors: Dimitrios Tsapralis; Ioannis Panayiotides; George Peros; Theodore Liakakos; Eva Karamitopoulou Journal: World J Gastroenterol Date: 2012-01-14 Impact factor: 5.742